Atara Biotherapeutics, Inc. - Common Stock (ATRA)

Historical Holders from Q4 2014 to Q3 2025

Symbol
ATRA on Nasdaq
CUSIP
046513107
Type / Class
Equity / Common Stock
Shares outstanding
8.56M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
15
Holdings value
$215
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
1
Number of buys
1
Average Value change %
+0%
Average buys %
+0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Atara Biotherapeutics, Inc. - Common Stock (ATRA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Panacea Innovation Ltd 20% +0.05% 1.71M +4.54% Panacea Innovation Limited Aug 15, 2025
Adiumentum Capital Fund I LP 19.99% 1.37M Adiumentum Capital Fund I LP May 14, 2025

Institutional Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 15 $215 +$215 $14.33 1
2025 Q1 0 $0 -$839 0
2024 Q4 63 $839 $13.32 2
2024 Q3 35 $285 -$1.51M $8.14 1
2024 Q2 182K $1.51M -$88.6M $8.50 5
2024 Q1 83.3M $57.8M +$13.9M $0.69 80
2023 Q4 52K $26.7K -$34.5K $0.51 2
2023 Q3 85.4M $126M -$2.7M $1.48 106
2023 Q2 89.6M $144M -$26M $1.61 113
2023 Q1 103M $298M +$14.4M $2.90 122
2022 Q4 97.3M $319M -$2.3M $3.28 134
2022 Q3 90.4M $342M -$18.5M $3.78 142
2022 Q2 87.7M $683M +$4.02M $7.79 128
2022 Q1 97.9M $909M +$12.5M $9.29 137
2021 Q4 92.5M $1.46B +$80.4M $15.76 131
2021 Q3 89.7M $1.57B +$68.6M $17.90 139
2021 Q2 86M $1.31B +$14.8M $15.55 144
2021 Q1 86.1M $1.24B -$11.3M $14.36 148
2020 Q4 82.5M $1.62B +$50.6M $19.63 141
2020 Q3 82.4M $1.07B +$62.3M $12.96 135
2020 Q2 76.4M $1.11B +$284M $14.57 116
2020 Q1 59.7M $507M +$1.17M $8.51 102
2019 Q4 58.2M $958M +$38.7M $16.47 110
2019 Q3 56M $791M +$105M $14.12 106
2019 Q2 50.3M $1.01B +$23.2M $20.11 113
2019 Q1 48.8M $1.94B +$25M $39.75 117
2018 Q4 48.2M $1.68B +$62.6M $34.74 118
2018 Q3 46.3M $1.92B -$3.17M $41.35 114
2018 Q2 46.5M $1.71B +$111M $36.75 122
2018 Q1 43.4M $1.69B +$555M $39.00 112
2017 Q4 29.8M $541M +$34.9M $18.10 81
2017 Q3 26.6M $441M +$15.3M $16.55 80
2017 Q2 25.7M $360M +$19.5M $14.00 78
2017 Q1 24M $493M +$57M $20.55 81
2016 Q4 23.2M $329M +$7.52M $14.20 81
2016 Q3 22.4M $479M +$15.4M $21.39 71
2016 Q2 21.6M $486M +$46.7M $22.51 69
2016 Q1 19.8M $377M +$7.11M $19.03 68
2015 Q4 19.3M $509M -$20.9M $26.41 83
2015 Q3 19.5M $612M +$193M $31.44 86
2015 Q2 13.1M $691M +$108M $52.76 74
2015 Q1 11.2M $462M +$186M $41.57 52
2014 Q4 6.73M $172M +$162M $26.75 39